Email:
global@GCP-ClinPlus.com
Recently, Santen Pharmaceutical (global leadership from Japan, US, and China) visited GCP ClinPlus for in‑depth discussions on data management, FSP collaboration, and AI applications in clinical development. This marks a new phase in our strategic partnership with this global ophthalmology leader.
As an AI‑driven, full‑service intelligent CRO, GCP ClinPlus has built distinctive strengths in ophthalmology:
Covering both rare and common eye diseases: AMD, retinitis pigmentosa, choroideremia, LCA, as well as cataract, dry eye, glaucoma, and more.
Trusted by top Japanese pharma: We have provided high‑quality services to Santen, Otsuka, Taiho, Sumitomo, Daiichi Sankyo, Astellas, and other leading Japanese companies – earning a strong reputation in data management, statistical programming, and global project delivery.
By the numbers: 23+ years, 2,300+ projects, 200+ MRCTs, 220+ approvals (incl. 4 FDA NDAs). Our proprietary AI‑powered ClinX platform continues to drive clinical innovation.
GCP ClinPlus looks forward to partnering with global innovators to accelerate ophthalmology therapies from lab to patients through professional expertise and data‑driven solutions.
global@gcp-clinplus.com
#Ophthalmology #ClinicalCRO #DataManagement #AIDrugDevelopment #Santen #GCPClinPlus